Anti-cancer Drug-Induced Kidney Disorder - Mechanism, Diagnosis, and Treatment

Introduction

The discovery of anti-cancer medications has revolutionized the treatment of cancer, which continues to be a major worldwide health burden. However, using these powerful therapeutic drugs is frequently linked to several negative side effects, including renal problems. The kidneys are vulnerable to damage brought on by drugs since they are essential for the metabolism and excretion of drugs. Anti-cancer medication-induced kidney problems can negatively affect cancer patients' response to therapy and general quality of life.

Acute kidney injury (AKI), chronic kidney disease (CKD), or nephrotic syndrome are three possible signs of drug-induced kidney damage. In order to create efficient prevention and therapeutic plans, it is essential to have a complete grasp of the processes at play in these diseases since they can result in renal dysfunction, electrolyte imbalances, and possible long-term consequences.

What Are Anti-cancer Drug-Induced Kidney Disorders?

Renal problems caused by anti-cancer medication usage are referred to as anti-cancer medication-induced renal diseases. Although these medications are successful in treating cancer, they can harm the kidneys and result in diseases including acute renal injury, chronic kidney disease, or nephrotic syndrome. Diverse mechanisms, such as direct toxicity to renal cells, vascular damage, immune-mediated responses, or abnormalities in electrolyte balance, can cause kidney injury. Preventive measures, supportive care, immunosuppressive medication, and, in severe situations, renal replacement therapy are used in the management of various kidney illnesses. In order to reduce the impact of these consequences on treatment results and patient well-being, early detection and action are essential.

What Is the Mechanism of Anti-cancer Drug-Induced Kidney Disorder?

• Direct Renal Toxicity: Some anti-cancer medications have toxic effects that are directly felt by the renal cells, causing cellular damage and deteriorating kidney function. Cisplatin, Methotrexate, and Ifosfamide are a few examples. These medications may result in interstitial nephritis, glomerular damage, or tubular injury.

• Vascular Damage: Some anticancer medications might cause vascular damage, which can alter renal blood flow and result in ischemia injury. Bevacizumab and Sunitinib are examples of VEGF inhibitors that are known to increase blood pressure and result in thrombotic microangiopathy (formation of small blood clots in the small blood vessels) in the kidneys.

• Immune-Mediated Injury: Immunotherapy drugs like immune checkpoint inhibitors can cause immune-mediated kidney diseases such as glomerulonephritis (inflammation of the glomerulus) and acute interstitial nephritis (inflammation of the interstitial part of the kidney). In order to stop irreparable kidney damage, these adverse effects frequently need to be promptly identified and managed.

• Metabolic Disturbances: Renal failure can result from the disruption of electrolyte balance caused by several anti-cancer medications. Tyrosine kinase inhibitors, for instance, may result in hypophosphatemia (low phosphate) and hypomagnesemia, which might affect renal tubular function and harm kidney health.

How Is the Clinical Presentation?

Typical warning signs and symptoms include:

• Urination Changes: Increased frequency of urination, decreased urine production (oliguria), or the presence of blood in the urine (hematuria).

• Renal Function Abnormalities: Elevated blood creatinine levels, which signify compromised kidney function, are a sign of abnormal renal function. Blood urea nitrogen (BUN) levels may rise, and the glomerular filtration rate (GFR) may decline as a result.

• Electrolyte Imbalances: Impaired renal tubular function can lead to electrolyte imbalances such as hyperkalemia (high potassium levels) or hypomagnesemia (low magnesium levels).

• Proteinuria: The presence of too much protein in the urine might be a sign of kidney filtration problems and glomerular injury.

• Edema: Swelling brought on by fluid retention as a result of impaired kidney function, especially in the legs, ankles, or the area around the eyes.

• Hypertension: High blood pressure that might result from vascular damage or electrolyte imbalances brought on by some anti-cancer medications.

• Other Symptoms: Other signs and symptoms of renal disease include fatigue, generalized weakness, nausea, vomiting, and appetite loss.

What Is the Diagnosis of Anti-cancer Drug-Induced Kidney Disorder?

An extensive assessment is required to diagnose renal abnormalities brought on by anti-cancer medications.

• Patient History: Evaluation of the patient's medical background, including any recent exposure to nephrotoxic substances or anti-cancer medications, baseline renal function, and a history of kidney disease.

• Physical Examination: Evaluation of vital signs, search for edema symptoms, search for further pertinent clinical findings.

• Laboratory Tests: Complete blood count (CBC), serum creatinine, blood urea nitrogen (BUN), electrolyte levels (potassium, magnesium, etc.), and blood urea nitrogen (BUN) measurements are used to evaluate renal function and spot any related abnormalities.

• Urinalysis: A urine sample is analyzed to look for hematuria, proteinuria, and other urinary abnormalities.

• Imaging Examinations: In order to evaluate the structure and function of the kidneys and spot any potential anomalies, imaging examinations like renal ultrasound, CT scan, or MRI may occasionally be carried out.

• Renal Biopsy: In some circumstances, a renal biopsy may be required to collect a tissue sample for in-depth examination and to direct particular treatment options, particularly when there is a suspicion of immune-mediated kidney damage.

What Are the Management Options for Anti-cancer Drug-Induced Kidney Disorders?

• Prevention: The risk of drug-induced kidney impairment can be reduced by taking preventative measures, including appropriate hydration, dosage changes depending on renal function, and close monitoring of renal parameters. Pharmacogenetic testing may assist in identifying individuals who are more likely to have renal toxicity and help direct individualized treatment plans.

• Supportive Care: It includes correcting electrolyte imbalances, stopping or adjusting the dosage of the offending medication, and starting renoprotective interventions like angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, which are necessary to manage drug-induced kidney disorders.

• Immunosuppressive Therapy: Immunosuppressive medications, such as corticosteroids, may be required to manage inflammation and maintain renal function in kidney diseases that are mediated by the immune system. But it is crucial to keep a close eye out for any potential infectious problems.

• Renal Replacement Therapy: Renal replacement therapy, such as hemodialysis or continuous renal replacement therapy, may be necessary in severe drug-induced kidney damage cases to sustain kidney function until recovery or as a transition to kidney transplantation.

Conclusion

In conclusion, renal diseases brought on by anti-cancer drugs may have a substantial influence on the success of cancer therapy and the well-being of patients. Healthcare providers may enhance patient outcomes, implement prompt treatments, and offer the best care possible for cancer patients while minimizing the impact on kidney function by having a thorough awareness of the clinical presentation and diagnosis of anti-cancer drug-induced kidney diseases.